Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06788964 · ClinicalTrials.gov registry record · Phase 2
Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)
A Phase 2 study of Relapsed or Refractory Large B-cell Lymphoma, sponsored by University of Utah.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT06788964: Recruiting Phase 2 study of Relapsed or Refractory Large B-cell Lymphoma, sponsored by University of Utah.
NCT06788964 is a Phase 2 study of Relapsed or Refractory Large B-cell Lymphoma that is actively recruiting participants, run by University of Utah. The registered enrollment target is 29 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06788964, a Phase 2 study of Relapsed or Refractory Large B-cell Lymphoma, is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this clinical trial is to learn if the study treatment Loncastuximab tesirine and Rituximab is safe and efficient before standard of care chimeric antigen receptor T-cell (CAR-T) therapy in patients with relapsed or refractory large B-cell lymphoma.
Primary Outcome
To evaluate the efficacy of SOC CAR T-cell therapy in patients with R/R large B-cell lymphoma following bridging with lonca-R.
Conditions Studied
Interventions
- DRUG Rituximab
- DRUG Loncastuximab Tesirine
Study Locations (1)
Utah
- Huntsman Cancer Institute at University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2025-08-25 |
| Est. Completion | 2030-03 |
| Phase | Phase 2 |
What NCT06788964 shows while recruiting
NCT06788964 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Relapsed or Refractory Large B-cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Rituximab is the first listed.
NCT06788964 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT06788964 about?
NCT06788964 is a clinical study titled "Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)". The purpose of this clinical trial is to learn if the study treatment Loncastuximab tesirine and Rituximab is safe and efficient before standard of care chimeric antigen receptor T-cell (CAR-T) therapy in patients with relapsed or refractory large B-cell lymphoma.
What is the current status of trial NCT06788964?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2025-08-25. Estimated completion is 2030-03.
What conditions does trial NCT06788964 study?
This clinical trial studies the following conditions: Relapsed or Refractory Large B-cell Lymphoma.
What interventions are being tested in trial NCT06788964?
The interventions under investigation include: Rituximab (DRUG), Loncastuximab Tesirine (DRUG).
Who is sponsoring clinical trial NCT06788964?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06788964 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory Large B-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06788964's enrollment target sits among peer trials
29 1669th of 2000 higher than 325 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI